India Globalization Capital’s (NYSE: IGC) Cannabis-Based Alzheimer’s Disease Treatment Increases Upside Potential
Alzheimer’s is a leading cause of dementia in adults in the United States IGC’s cannabis-based drug may reverse the buildup of beta-amyloid plaque Hyalolex and other phytocannabinoid-based drugs are fueling potential for the company’s market valuation growth Alzheimer’s disease is currently the sixth-leading cause of death in the nation and the most common cause of dementia in older individuals. The chronic neurodegenerative disease has had no cure or effective treatment for reducing its symptoms, but India Globalization Capital, Inc. (NYSE MKT: IGC) is seeking to change that with a potential blockbuster drug. Hyalolex, otherwise known as IGC-AD1, is a cannabis-based…